StockPriceToday
Marriott International Inc (MAR)
About Marriott International Inc
Marriott International Inc. operates as a leading hospitality company that manages, franchises, and licenses hotel, residential, and timeshare properties worldwide under numerous brand names. The company's global hotel presence has made MAR stock price highly sensitive to travel demand, economic conditions, and tourism industry trends.
Marriott's brand portfolio includes luxury brands like The Ritz-Carlton and St. Regis, premium brands like Marriott Hotels and Sheraton, and select-service brands like Courtyard and Fairfield Inn. The company's properties serve business and leisure travelers across various price points and market segments.
The company's Bonvoy loyalty program and direct booking initiatives help reduce distribution costs while enhancing customer retention. Marriott's expansion into alternative accommodations and extended-stay properties demonstrates its adaptation to changing travel preferences, affecting MAR stock price movements.
Marriott's asset-light business model generates fee revenue from management and franchise agreements while providing global scale advantages. The company's ability to adapt to changing travel patterns while maintaining brand strength remains important for its continued success and market leadership.
MAR Stock 12 Month Chart
Latest News for MAR
Marriott operates 1.8 million rooms across roughly 30 brands. At the end of 2025, luxury represented roughly 10% of total rooms, premium was 42%, select service was 46%, and midscale was 2%. Marriott, ...
Marriott International’s shares have surged past the broader benchmark and sector peers, and analysts are cautiously bullish on the stock’s growth potential.
Shares of Marriott International Inc. MAR rallied 1.26% to $373.81 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.61% to 7, ...
Other Popular Stocks
argenx SE is a biotechnology company developing antibody-based therapies for autoimmune diseases and cancer.
Ovid Therapeutics Inc. (OVID) is a biotechnology company developing therapies for rare neurological disorders with focus on epilepsy and other serious brain conditions affecting...
Acumen Pharmaceuticals Inc. is a clinical-stage biotechnology company developing precision medicine approaches for neurodegenerative diseases.